Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

CHEK2, breast cancer, and the understanding of clinical utility | Synapse

June 7, 2010

Ver artículo completo

CHEK2, breast cancer, and the understanding of clinical utility

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Robson M. CHEK2 , breast cancer, and the understanding of clinical utility.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Mark E. Robson (Mon,) studied this question.

synapsesocial.com/papers/6a1b65afdb618aee6aabd773 https://doi.org/https://doi.org/10.1111/j.1399-0004.2010.01444.x

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group2009 · 675 citations
2Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers2009 · 3,636 citations
3Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA22009 · 49 citations
4Heterozygous Germ Line <i>hCHK2</i> Mutations in Li-Fraumeni Syndrome1999 · 902 citations
5Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study2008 · 49 citations